End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
124 MXN | -2.36% | -.--% | -2.36% |
Sales 2024 * | 39.35M 655M 53.66M | Sales 2025 * | 58.17M 968M 79.31M | Capitalization | 75.81M 1.26B 103M |
---|---|---|---|---|---|
Net income 2024 * | -120M -2B -164M | Net income 2025 * | -77M -1.28B -105M | EV / Sales 2024 * | -1.31 x |
Net cash position 2024 * | 127M 2.12B 174M | Net cash position 2025 * | 54.53M 908M 74.35M | EV / Sales 2025 * | 0.37 x |
P/E ratio 2024 * |
-0.7
x | P/E ratio 2025 * |
-1.33
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 day | -2.36% | ||
3 months | -2.36% | ||
6 months | -4.62% | ||
Current year | -2.36% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 21-04-11 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 19-11-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 08-11-30 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Elan Ezickson
BRD | Director/Board Member | 60 | 19-12-11 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- MRNS Stock
- MRNS * Stock